Will X4 Pharmaceuticals stock go up?

According to Danelfin AI, X4 Pharmaceuticals has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (51.62%) is +0.80% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for X4 Pharmaceuticals stock?

The X4 Pharmaceuticals target price is $4.15 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold X4 Pharmaceuticals stock right now?

X4 Pharmaceuticals has today a Hold rating (AI Score 5/10), according to Danelfin AI. Its probability of beating the market in 3 months (51.62%) is +0.80% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether X4 Pharmaceuticals stock is a good buy .

Is X4 Pharmaceuticals undervalued right now?

Based on analysts, the average price target downside for X4 Pharmaceuticals is 0.00% (1Y). According to Danelfin AI, X4 Pharmaceuticals has today an AI Score of 5/10 (Hold Rating).

What was the price range of X4 Pharmaceuticals stock over the past 12 months?

The X4 Pharmaceuticals stock price range over the past 12 months has been $1.42 - $4.67.

What is going on with X4 Pharmaceuticals stock in the last 3 months?

The X4 Pharmaceuticals stock performance in the last quarter has been -4.59%.

Does X4 Pharmaceuticals offer dividend payments?

No, X4 Pharmaceuticals does not currently pay dividends.

What is the current market capitalization of X4 Pharmaceuticals?

X4 Pharmaceuticals's market cap is $389.54M, as of 2026-07-03 08:00.

X4 Pharmaceuticals Inc (XFOR) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

XFOR AI-Powered Stock Analysis

AI Score Explanation

AI Score

Hold

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, X4 Pharmaceuticals Inc today receives an AI Score of 5/10, which translates to a Hold rating. The stock has a 52% probability of outperforming the market in the next 3 months, which is 1% higher than the average probability of any stock (51%). Key positive contributors include Operating Cash Flow (Qtr Discrete) (impact +4.17%, bottom 20%), Industry (GICS) being Biotechnology (impact +2.07%), and Chart Pattern (90d) (impact +1.20%). On the negative side, the main detractors are Chart Pattern (252d) (impact -4.35%), Chart Pattern (504d) (impact -2.79%), and Fear & Greed Index (CNN) at 31 (impact -2.28%). Notable data points include Alpha 1Y in the top 10% (value 1.03), indicating strong risk-adjusted returns, and Analyst Lowest Price Upside also in the top 10% (value 1.22), suggesting even the most conservative analyst sees upside. However, Maximum Volatility is in the top 30% (value 6.37), reflecting high price fluctuation, and Performance (YTD) in the top 40% (value 3.75%) detracts slightly. Overall, the stock’s probability is only marginally above average, with technical chart patterns weighing heavily, while fundamentals and analyst sentiment provide some support, resulting in a neutral Hold rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Earnings Quality+4.17%
Stability and reliability of reported earnings
Valuation+0.94%
How the stock is priced relative to its fundamentals
Size & Liquidity+0.82%
Company size and trading liquidity
Volatility+0.65%
How much the stock price tends to fluctuate
Sentiment+0.20%
How analysts and the market view the stock

Momentum-5.39%
Direction and strength of recent price movements
Profitability-0.61%
Profitability and operating efficiency metrics

XFOR probability advantage of beating the market (3M):

+0.80%

Sentiment

X4 Pharmaceuticals (XFOR) has a Sentiment Score of 5/10 because, according to only sentiment analysis, it has a probability advantage of +0.74% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.04%) and the probability of XFOR (50.79%) of overperforming the market in the next 3 months, as determined by Danelfin AI’s sentiment analysis.

Average probability of any US-listed stock of beating the market (3M)50.04%
XFOR probability advantage of beating the market (only sentiment, 3M)+0.74%
XFOR probability of beating the market (3M)50.79%

XFOR probability advantage of beating the market (only sentiment, 3M): +0.74%

The AI-powered sentiment analysis of X4 Pharmaceuticals (XFOR) is only based on the 28 sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of XFOR:

Type	Alpha Signal	Probability Advantage Impact (3M)
Sentiment	Upgrade to Pro to unlock	-2.11%
Sentiment	Upgrade to Pro to unlock	-1.88%
Sentiment	Upgrade to Pro to unlock	-1.87%
Sentiment	Upgrade to Pro to unlock	+1.61%
Sentiment	Upgrade to Pro to unlock	+1.54%
Sentiment	Upgrade to Pro to unlock	+1.48%
Sentiment	Upgrade to Pro to unlock	+1.25%
Sentiment	Upgrade to Pro to unlock	+0.77%
Sentiment	Upgrade to Pro to unlock	-0.49%
Sentiment	Upgrade to Pro to unlock	+0.45%
Sentiment	Upgrade to Pro to unlock	-0.28%
Sentiment	Upgrade to Pro to unlock	+0.27%
Sentiment	Upgrade to Pro to unlock	-0.26%
Sentiment	Upgrade to Pro to unlock	+0.19%
Sentiment	Upgrade to Pro to unlock	+0.15%

Rest of Alpha Signals: -0.05%

XFOR probability advantage of beating the market (only sentiment, 3M)Total:+0.74%
XFOR Sentiment Score

Significant changes Vs previous day

XFOR Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$4.15
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

XFOR Proven Hold Signal & Price Forecast

This is the price chart for XFOR from January 2, 2026 until today. The chart indicates, in yellow, the 55 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

XFOR Average Past Performance & Win Rate

Three months after its 1020 Hold signals since July 2026, XFOR had an average performance of xxxxxx and a xxxxxx Win rate (positive performance).

1020 Past XFOR Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-44.60%
Average Alpha				-60.38%
Win Rate (% Positive Perf.)				10.01%
% Positive Alpha				5.23%

XFOR Frequently Asked Questions

Will X4 Pharmaceuticals stock go up?
According to Danelfin AI, X4 Pharmaceuticals has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (51.62%) is +0.80% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for X4 Pharmaceuticals stock?
Is it a good time to buy, sell, or hold X4 Pharmaceuticals stock right now?
Is X4 Pharmaceuticals undervalued right now?
What was the price range of X4 Pharmaceuticals stock over the past 12 months?
What is going on with X4 Pharmaceuticals stock in the last 3 months?
Does X4 Pharmaceuticals offer dividend payments?
What is the current market capitalization of X4 Pharmaceuticals?

X4 Pharmaceuticals Inc Company Profile

X4 Pharmaceuticals, Inc., an advanced clinical-stage biopharmaceutical firm, centers its efforts on pioneering unique therapeutics targeted at managing and treating uncommon illnesses. The flagship product in its lineup is mavorixafor, a fine-tuned molecule that inhibits the C-X-C chemokine receptor type 4 (CXCR4). Currently undergoing stage III clinical evaluation, mavorixafor serves as a potential remedy for patients suffering from myelokathexis syndrome among other conditions like infections and hypogammaglobulinemia. Further evaluations are being carried out in stage II clinical trials to ascertain its effectiveness for congenital or idiopathic neutropenia.

Additionally, X4 Pharmaceuticals is working on X4P-003 and X4P-002, both antagonists of CXCR4. These novel treatments are intended for primary immune deficiencies and disorders dependent on CXCR4, along with diseases affecting the blood-brain barrier respectively.

As part of its strategic alliances, X4 Pharmaceuticals has inked a licensing accord with Abbisko Therapeutics Co Ltd. This partnership paves the way for the mutual development, manufacture, and marketing of mavorixafor blended with checkpoint inhibitors or alternative agents to address oncological indications.

Rooted in Boston, Massachusetts - this is where X4 Pharmaceuticals commands its operations from.

Sector:
Country:United States
Industry:
Address:61 North Beacon Street, 4th Floor, Boston
Employees:45
Website:x4pharma.com

Pros

Orphan drug designation benefits for market exclusivity

Targeting unmet medical needs in rare immunodeficiencies

CXCR4 antagonist mechanism of action differentiation

Potential for pipeline expansion across multiple indications

High patient switching costs for established rare disease therapies

Cons

High clinical trial failure risk for novel drug candidates

Substantial capital requirements for drug development

Limited addressable patient population for ultra-rare diseases

Intense regulatory scrutiny for novel therapies

Reimbursement challenges for high-cost specialty pharmaceuticals

XFOR Stock AI Analysis High Risk